• Clinical and Experimental Pediatrics
• /
• 제65권3호
• /
• pp.115-126
• /
• 2022

Retinopathy of prematurity (ROP) is among the most common causes of childhood blindness. Three phases of ROP epidemics have been observed worldwide since ROP was first described in the 1940s. Despite advances in neonatal care, the occurrence of ROP and associated visual impairment has been increasing somewhere on Earth and remains difficult to control. Conventional treatment options for preventing ROP progression include retinal ablation using cryotherapy or laser therapy. With the emergence of anti-vascular endothelial growth factor (anti-VEGF) treatment for ocular diseases, the efficacy and safety of anti-VEGF therapy for ROP have recently been actively discussed. In the advanced stage of ROP with retinal detachment, surgical treatment including scleral buckling or vitrectomy is needed to maintain or induce retinal attachment. At this stage, the visual outcome is usually poor despite successful anatomical retinal attachment. Therefore, preventing ROP progression by timely screening examinations and treatment remains the most important part of ROP management.

• Clinical and Experimental Pediatrics
• /
• 제52권1호
• /
• pp.22-27
• /
• 2009

Retinopathy of prematurity (ROP) is a major cause of blindness that affects premature infants. With advances in neonatology, ROP is likely to emerge as the most serious problem of vision loss in children even in developed countries; such a situation could be called the third epidemic of ROP. However, controversy and uncertainty still surround favorable outcomes of ROP. For successfully controlling ROP, timely and accurate screening is crucial because early treatment leads to favorable outcomes. Standard guidelines, including ROP classification, have provided satisfactory instructions for the screening and treatment of ROP. To improve the structural and functional outcomes of ROP, optimizing the timing of surgical interventions including cryotherapy, laser-photocoagulation, encircling, and vitrectomy is essential; these interventions can prevent the sequelae of ROP. It is essential for the neonatologist and the ophthalmologist to cooperate extensively for the successful treatment of ROP.

• Neonatal Medicine
• /
• 제28권1호
• /
• pp.7-13
• /
• 2021

Purpose: To evaluate the risk factors and effects of fluctuations in oxygen saturation on the occurrence and severity of retinopathy of prematurity (ROP). Methods: From January 1, 2013 to January 31, 2020, 260 patients hospitalized in the neonatal intensive care unit of Ajou University Hospital were retrospectively analyzed. Results: Sixty-six patients (25%) were diagnosed with ROP; of them 39 required treatment. In the multivariate regression analysis of ROP severity, the odds ratio (OR) of gestational age was 0.32 (95% confidence interval [CI], 0.22 to 0.47; P<0.0001). The OR of saturation of peripheral oxygen (SpO₂) fluctuations at the 4th week after birth was 1.02 (95% CI, 1.02 to 1.12; P=0.041). Conclusion: SpO₂ fluctuations in premature infants younger than 30 weeks' gestational age affects ROP severity, especially at the 4th week of life.

• Clinical and Experimental Pediatrics
• /
• 제58권2호
• /
• pp.52-59
• /
• 2015

Purpose: This study aimed to investigate the relative weight gain at 2-week intervals up to 6 weeks after birth to predict retinopathy of prematurity (ROP) requiring treatment among very low birth weight infants. Methods: A total of 211 preterm infants with birth weights <1,500 g and gestational age <32 weeks were retrospectively reviewed. The main outcome was the development of ROP requiring treatment. Body weight measurements were recorded daily. Relative weight gains (g/kg/day) were calculated at the second, fourth, and sixth week after birth. Results: Of the 211 infants, 89 developed ROP, of which 41 spontaneously regressed and 48 with early treatment of ROP type I required laser treatment. The relative weight gain at 2, 4, and 6 weeks postnatal age was significantly lower in infants with ROP requiring treatment than in infants without ROP or those with spontaneous regression (P<0.001, P=0.005, and P=0.004, respectively). On logistic regression, poor relative weight gain in the first 2 weeks was found to be related to ROP requiring treatment (adjusted odds ratio, 0.809; 95% confidence interval, 0.695-0.941; P=0.006). Relative weight gain at 2 weeks postnatal age was significantly lower in infants with ROP requiring treatment compared to that in ROP requiring no treatment (P=0.012). Conclusion: Poor postnatal weight gain in the first 2 weeks of life is an important and independent risk factor for ROP requiring treatment. Postnatal weight gain can predict the development of severe ROP requiring treatment.

• Child Health Nursing Research
• /
• 제25권3호
• /
• pp.255-261
• /
• 2019

Purpose: This study compared the pain-relieving effects of human milk, sucrose, and distilled water during examinations for retinopathy of prematurity. Methods: Forty-five preterm infants were randomly assigned to receive a pacifier dipped in one of three solutions: human milk (n=14), 24% sucrose (n=15), or distilled water (n=16), 2 minutes before an eye examination. Their pain score, pulse rate, and oxygen saturation were measured at three time points: 5 minutes before the examination, 30 seconds after speculum introduction, and 2 minutes after the examination. Results: The infants' mean gestational age and weight at birth were $33.1{\pm}2.1$ weeks and $1,842{\pm}470g$, respectively. There were no between-group differences in pain relief during the eye examination. The pain score significantly increased both during (p<.001) and after the examinations (p=.003). Oxygen saturation decreased during the examinations (p<.001); however, the infants in the 24% sucrose group showed higher oxygen saturation (p=.047) during the examinations than the infants in the other groups. Conclusion: Sucking on a pacifier dipped in human milk or 24% sucrose did not reduce the pain associated with eye examinations in preterm infants. Pacifiers dipped in sucrose can be used to maintain better oxygen saturation during these examinations.

• 제어로봇시스템학회:학술대회논문집
• /
• 제어로봇시스템학회 2004년도 ICCAS
• /
• pp.312-316
• /
• 2004

The paper presents a technique to identify the boundary of the optic disc in infant retinal digital images using an approach based on active contours (snakes). The technique can be used to be develop a automate system in order to help the ophthalmologist's diagnosis the retinopathy of prematurity (ROP) disease which may occurred on preterm infant,. The optic disc detection is one of the fundamental step which could help to create an automate diagnose system for the doctors we use a new kind of active contour (snake) method has been developed by Chenyang et. al. [1], based on a new type of external force field, called gradient vector flow, or GVF. GVF is computed as a diffusion of the gradient vectors of a gray-level or binary edge map derived from the image. The testing results on a set of infant retinal ROP images verify the effectiveness of the proposed methods. We show that GVF has a large capture range and it's able to move snakes into boundary concavities of optic disc and finally the optic disk boundary was determined.

• 제어로봇시스템학회:학술대회논문집
• /
• 제어로봇시스템학회 2004년도 ICCAS
• /
• pp.321-325
• /
• 2004

Retinopathy of Prematurity (ROP) is a common retinal neovascular disorder of premature infants. It can be characterized by inappropriate and disorganized vessel. This paper present a method for blood vessel detection on infant retinal images. The algorithm is designed to detect the retinal vessels. The proposed method applies a Lapalacian of Gaussian as a step-edge detector based on the second-order directional derivative to identify locations of the edge of vessels with zero crossings. The procedure allows parameters computation in a fixed number of operations independent of kernel size. This method is composed of four steps : grayscale conversion, edge detection based on LOG, noise removal by adaptive Wiener filter & median filter, and Otsu's global thresholding. The algorithm has been tested on twenty infant retinal images. In cooperation with the Digital Imaging Research Centre, Kingston University, London and Department of Opthalmology, Imperial College London who supplied all the images used in this project. The algorithm has done well to detect small thin vessels, which are of interest in clinical practice.

• Molecules and Cells
• /
• 제41권8호
• /
• pp.771-780
• /
• 2018

Angiogenesis must be precisely controlled because uncontrolled angiogenesis is involved in aggravation of disease symptoms. Vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR-2) signaling is a key pathway leading to angiogenic responses in vascular endothelial cells (ECs). Therefore, targeting VEGF/VEGFR-2 signaling may be effective at modulating angiogenesis to alleviate various disease symptoms. Oleanolic acid was verified as a VEGFR-2 binding chemical from anticancer herbs with similar binding affinity as a reference drug in the Protein Data Bank (PDB) entry 3CJG of model A coordination. Oleanolic acid effectively inhibited VEGF-induced VEGFR-2 activation and angiogenesis in HUVECs without cytotoxicity. We also verified that oleanolic acid inhibits in vivo angiogenesis during the development and the course of the retinopathy of prematurity (ROP) model in the mouse retina. Taken together, our results suggest a potential therapeutic benefit of oleanolic acid for inhibiting angiogenesis in proangiogenic diseases, including retinopathy.

• Korean Journal of Ophthalmology
• /
• 제32권6호
• /
• pp.451-458
• /
• 2018

Purpose: To investigate the efficacy, safety, and anatomical outcomes associated with intravitreal anti-vascular endothelial growth factor (VEGF) treatment of retinopathy of prematurity (ROP). Methods: We performed a retrospective review of intravitreal anti-VEGF (bevacizumab or ranibizumab) treatment of 153 eyes (83 infants) diagnosed with ROP at two tertiary hospitals from June 2011 to January 2017. The primary outcome was the rate of recurrence requiring additional treatment; secondary outcomes included incidence of major complications and final refractive error. Results: A total of 101 eyes were treated with bevacizumab, and 52 with ranibizumab. The bevacizumab and ranibizumab groups were characterized by mean birthweights of $941.8{\pm}296.1$ and $1,257.7{\pm}514.5g$, gestational ages at birth of $26.9{\pm}1.9$ and $28.1{\pm}3.2$ weeks, and postmenstrual ages at treatment of $40.4{\pm}2.4$ and $39.2{\pm}2.3$ weeks, respectively. The two groups differed significantly in birthweights and gestational ages at birth, but not in postmenstrual ages at treatment. The mean follow-up duration was $30.9{\pm}18.4$ months for the bevacizumab group, and $13.9{\pm}12.5$ months for ranibizumab. More cases were classified as zone 1 ROP in the ranibizumab group (44.2% vs. 11.9%, p < 0.001). Major surgical interventions included scleral encircling and vitrectomy (one and two eyes, respectively, both in the bevacizumab group). Retinal detachment was noted in one eye treated with bevacizumab. There was no significant difference in the most recent spherical equivalence for the two groups ($+0.10{\pm}3.66$ and $+0.22{\pm}3.00$ diopters for bevacizumab and ranibizumab, respectively). Univariable analysis revealed that only ROP stage influenced the occurrence of major complications (odds ratio, 9.046; p = 0.012). Conclusions: Intravitreal anti-VEGF treatment of ROP with both bevacizumab and ranibizumab achieved stable retinal vascularization with a low rate of complications and recurrence. Ranibizumab achieved similar anatomical outcomes as bevacizumab, without additional risk for major complications.

• Clinical and Experimental Pediatrics
• /
• 제52권1호
• /
• pp.50-55
• /
• 2009

목 적 : 최근 신생아 집중치료의 발전으로 미숙아의 생존율이 증가하면서 미숙아 망막병증도 증가하는 추세이다. 재태 연령 및 출생체중과 미숙한 망막이 중요한 위험인자이지만, 이 외에 무호흡, 패혈증, 인공호흡기의 사용, 장기간의 산소사용 역시 유의한 위험 인자로 알려져 있다. 이에 본 연구는 만성 폐질환 환아에서 nasal cannula를 통한 저농도 산소($FiO_2$ 25% 미만)의 사용 기간이 미숙아 망막병증의 진행에 미치는 영향을 알아보고, 미숙아 망막병증의 예방 및 진행의 완화에 도움을 주고자 본 연구를 시행하였다. 방 법 : 2001년 2월 1일부터 2006년 1월 31일까지 본원 출생아중 재태 연령 37주 미만이면서 출생체중 1,750 g 미만의 생존한 미숙아들로, 안저 검사를 받고 최소 6개월 이상 추적관찰이 가능했던 273명의 미숙아를 대상으로 의무기록을 기초로 후향적 분석을 통해 미숙아 망막병증의 발생에 영향을 미치는 여러 위험인자들을 검토하고, 저농도 산소의 사용 기간이 미숙아 망막병증의 발생과 임상경과 및 예후에 미치는 영향을 조사하였다. 만성 폐질환은 생후 28일 혹은 재태주령 36주가 되는 시점에 산소 의존도가 있었던 경우로 정의하였다. 결과 : 미숙아 망막병증의 발생에 가장 큰 영향을 미치는 인자로는 짧은 재태연령과 적은 출생체중이었고, 기타 무호흡, 표면활성제의 사용, 인공호흡기, 신생아 호흡곤란 증후군, 뇌실내 출혈 등의 순으로 상대적 위험도가 높았다. 저농도 산소 사용 기간이 길어질수록 미숙아 망막병증의 발생률은 높아지고, 미숙아 망막병증의 발병 시기는 지연되는 경향을 보였다. 수술적 치료를 받은 환아들에서 일단 미숙아 망막병증이 발병한 후에는 수술적 치료가 필요한 정도의 심각한 미숙아 망막병증으로 진행하는 기간 간격은 짧아지는 경향을 보였으며, 특히 만성 폐질환 환아군에서 산소를 투여하고 있는 기간 중보다는 산소를 중단한 이후에 미숙아 망막병증이 급격하게 진행되는 경향을 보였다. 결론 : 심각한 미숙아 망막병증의 발병 및 급속한 진행을 예방하기 위하여 가능한 한 저농도 산소라도 사용기간을 줄이고, 산소 사용 중단 이후에는 좀 더 적극적인 추적 안저 검사를 해야 할 것으로 생각된다.